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Birt-Hogg-Dube´ (BHD) syndrome is an autosomal-dominantly inherited cancer syndrome characterized by
fibrofolliculomas, lung cysts leading to pneumothorax, and chromophobic/oncocytic renal cell carcinoma. The
disease is caused by heterozygous mutations in the BHD gene encoding folliculin and all mutations reported
putatively lead to protein truncation. Although the function of folliculin is unknown, it is thought to be a tumor
suppressor, with loss of heterozygosity (LOH) initiating tumor formation. Here, we report on four novel BHD
gene mutations, including two splice-site mutations, in patients presenting with skin lesions only. We further
show that LOH cannot be detected in fibrofolliculomas from three patients, suggesting that for the
manifestation of cutaneous tumors in BHD syndrome haplo-insufficiency of folliculin is sufficient to initiate
uncontrolled growth. Renal microscopic oncocytosis in BHD is considered as a precursor to malignant kidney
tumors and may likewise be the result of haplo-insufficiency, with somatic second-hit mutations or LOH giving
rise to malignancy later in life.
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INTRODUCTION
Birt-Hogg-Dube´ (BHD) syndrome (OMIM 135150) is a rare
tumor syndrome that is inherited in an autosomal dominant
manner. The clinical hallmarks of the disease are fibrofolli-
culomas, benign hair follicle tumors with a typical histology,
consisting of anastomosing epithelial strands surrounding a
fibrovascular stroma (Scalvenzi et al., 1998). Besides the
cutaneous signs, pneumothorax is a common feature of the
disorder, with the highest incidence before the age of 40
years (Zbar et al., 2002). One study reported on a BHD family
that apparently presented with pneumothorax exclusively
(Painter et al., 2005). Additionally, the occurrence of chromo-
phobic/oncocytic hybrid and pure chromophobic kidney
tumors has been reported, mostly affecting both kidneys
and predominantly manifesting after the age of 40 years
(Zbar et al., 2002).
The disease is caused by mutations in the BHD gene that
encodes folliculin, a cytoplasmic protein with a predicted size
of 64 kDa. Alternative splicing of the BHD gene results in two
isoforms of folliculin, a full-length form and one that uses an
initiation codon in intron 6 (Nickerson et al., 2002). The
function of folliculin and its alternate splice variant is presently
unknown. All germline mutations in patients suffering from
BHD syndrome described so far are splice-site mutations or
insertions/deletions that likely result in protein truncation and
haplo-insufficiency. In this study, we identified five mutations
in BHD syndrome patients of which four are novel. These
include two deletions and one insertion that lead to frameshifts
and two splice-site mutations. RNA studies revealed that one
splice-site mutation results in the absence of identifiable
aberrant reverse transcriptase-PCR (RT-PCR) products, whereas
the other one leads to exon skipping.
Previously, the occurrence of loss of heterozygosity (LOH)
at the BHD locus has been studied in sporadic kidney tumors.
From these data, it appears that LOH of the BHD gene can be
found in a minority of such sporadic renal malignancies
(Khoo et al., 2003). In BHD patients though, second-hit
somatic mutations appear to be more frequent (Vocke et al.,
2005). Despite these data obtained in renal tissue, it has not
yet been studied if folliculin also behaves as a typical tumor
suppressor in the skin. To determine whether LOH or second-
hit somatic mutations play a role in the pathogenesis of the
cutaneous tumors arising in BHD syndrome, we examined
fibrofolliculomas from three different patients. Our data
suggest that LOH or second-hit somatic mutations are most
likely not involved in the pathogenesis of these skin tumors.
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RESULTS
Mutation analysis
In all patients studied we detected mutations in the BHD
gene, consisting of one insertion, two deletions, and two
splice-site mutations (one at the donor, the other one at
the acceptor splice site), designated 1277insC, 420delC,
1408_1418delGGGAGCCCTGT, IVS10-2A4G, and 1300G4C,
respectively (Table 1). These sequence deviations were
absent in 96 healthy control individuals as confirmed by
restriction enzyme digestion. To analyze the consequences of
the two latter mutations, we performed RNA analyses.
RT-PCR analyses
In patients MH63 and MC60 carrying the mutations
1300G4C and IVS10-2A4G, respectively, we first per-
formed RT-PCR in order to study the specific splicing pattern
and the consequences arising from these sequence deviations
on the cDNA level.
Mutation 1300G4C theoretically results in the substitu-
tion of a glutamine residue by a glutamic acid residue with
the putative designation E434Q. Because it affects the last
coding nucleotide of exon 11, we reasoned that this mutation
might result in aberrant mRNA splicing. This hypothesis was
subsequently confirmed by demonstrating skipping of exon
11 in patient MH63 as a consequence of this mutation
(Figure 1). In patient MC60, we did not detect any aberrant
PCR products (data not shown).
LOH studies
In fibrofolliculomas obtained from patients MH63, MC60,
and MMC59, we sought for LOH or second-hit mutations on
the DNA level. Comparative sequence analyses for all coding
exons of BHD performed on DNA extracted from a skin
tumor biopsy versus genomic DNA isolated from peripheral
blood lymphocytes did not reveal any sequence deviations
indicative of LOH or second-hit mutations. The mutations
found in leukocyte DNA were also present in the hetero-
zygous state in DNA derived from the fibrofolliculomas. To
further rule out the presence of LOH, we performed laser
capture microdissection on a tumor sample from individual
TQ27 (Figure 2a). Multiple tumor fields were dissected and in
the DNA isolated from all of those, we found the 11 bp
deletion in a heterozygous state (Figure 2b). To determine if
LOH occurs through promoter hypermethylation, DNA from
lymphocytes as well as from fibrofolicullomas was tested
with a methylation-sensitive PCR and subsequent sequen-
cing. We could not detect any differences between sequence
traces from the three fibrofolliculoma biopsies and from
lymphocytes.
DISCUSSION
Here, we studied five patients with BHD syndrome and
detected five distinct sequence deviations, including one
insertion, two deletions, and two splice-site mutations. Of
these, four are novel. Mutation 1277insC has been described
previously as 1733insC (Nickerson et al., 2002). Our
numbering differs because we take the first nucleotide of
the initiation codon as a starting point (exon 4), instead of the
first non-coding exon of the BHD gene. We also sought for
evidence of LOH in fibrofolliculomas from three of these
patients.
Table 1. Mutations identified in the BHD gene of BHD patients
Patient Exon/intron Nucleotide change Codon location Mutation type
TQ27 Exon 12 1408_1418delGGGAGCCCTGT G470 FS
MH63 Exon 11 1300G4C E434 SS
MC60 Intron 10 IVS10-2A4G — SS
MMC59 Intron 10 IVS10-2A4G — SS
MB61 Exon 6 420delC P140 FS
KD63 Exon 11 1277insC H429 FS
BHD, Birt-Hogg-Dube´; FS, frameshift; SS, splice site.
9 10 11 12
9 10 12 13
500 bp
376 bp
13
Figure 1. RT-PCR results from a fibrofolliculoma biopsy of patient MH63
with primers BHD9cF and BHD13cR2. Lane 1, mutant; lane 2, RT control;
lane 3, wild-type. The RT control is negative, ruling out contamination with
genomic DNA. Sizes of the PCR products are on the right and illustrations
representing the products on the left.
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BHD syndrome shows considerable clinical and genetic
heterogeneity, which is reflected by previous data as well as
our own observations in this study. The symptoms encoun-
tered in our patients and their family histories confirm other
reports in which BHD syndrome is shown to be clinically
heterogeneous, with kidney tumors being relatively rare
(Schmidt et al., 2005). Although one study suggests that
pneumothorax can be the only clinical sign (Graham et al.,
2005; Painter et al., 2005), we consider this rather unlikely,
based on our own experience with several patients and their
families, because all affected persons examined by us
developed folliculomas after the age of 35 years. These skin
lesions might easily escape detection because they are rather
subtle. With this in mind, it probably would be of interest to
re-examine the family reported by Painter et al. (2005)
(Graham et al., 2005).
To date, several mutations in the BHD gene have been
reported, including insertions, deletions, and splice-site
mutations. About 40–50% are insertions/deletions in a
hypermutable C(8)-tract in exon 11 (Lamberti et al., 2005).
The two deletion mutations, 420delC and 1408_1418delGG-
GAGCCCTGT (Table 1), cause frameshifts and premature
termination codons and might lead to haplo-insufficiency as
a result of protein truncation or nonsense-mediated mRNA
decay.
The mutation in MH63 is interesting, because it affects
the last nucleotide of exon 11, changing a G to a C, thus
presumably resulting in a missense mutation, E434Q.
However, the splicing pattern of our subsequent RT-PCR
analysis showed that the mutation affected mRNA splicing,
causing the skipping of exon 11. The second splice-site
mutation detected in patient MC60 might result in partial
inclusion of intron 11 with frameshift (NetGene2, http://
www.softberry.com) and subsequent nonsense-mediated
mRNA decay initiated by stop codons in the mRNA, as
reported previously (Zeniou et al., 2004). In support of this
prediction, we were not able to demonstrate any mutant
mRNA splice products upon RT-PCR.
All mutations reported in BHD syndrome, including the
ones described here, are predicted to result in haplo-
insufficiency. Interestingly, neither in humans nor in the
Nihon rat model of BHD (Okimoto et al., 2004), missense
mutations have been described yet. By contrast, however, in
a canine model of the disease, a missense mutation in the
BHD gene has been reported (Lingaas et al., 2003). The
mutated histidine (H255) in the canine folliculin protein is
highly conserved among various mammalian species, includ-
ing mouse, rat, cow, dog, and human, suggesting that it is
crucial to protein function. Mutations that cause BHD
syndrome-like symptoms in the dog might therefore be
expected to cause loss-of-function of the mutated allele.
Because the canine phenotype differs from the human one in
certain aspects, it would also be conceivable that it is not
caused by haplo-insufficiency. Elucidation of the function of
folliculin will help to resolve this matter.
It has been suggested that folliculin behaves as a typical
tumor suppressor protein, with loss-of-function of the
remaining, healthy allele resulting in tumorigenesis. How-
ever, the results of our RT-PCR analyses of tumor biopsies in
two patients showed that at least in one patient (MH63)
biallelic gene expression was always present. These data
indicate that LOH or promoter hypermethylation was absent
in the bulk of the skin lesions. In the other patient (MC60), we
could only demonstrate the presence of a wild-type allele.
We can rule out the possibility of promoter hypermethylation
in the remaining healthy allele within the tumor based on the
results of the bisulfite PCR, also in the other two patients thus
examined. Analysis of DNA obtained from tumor biopsies
from three patients further suggests that somatic second-hit
mutations are not present. Finally, laser capture microdissec-
tion of tumor tissue convincingly demonstrated heterozygo-
sity for the germline mutation, demonstrating that low
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Figure 2. Micrographs of the laser capture microdissection procedure. The
fibrofolliculoma is colored magenta. The panel labeled ‘‘after’’ shows the
situation after dissection of one tumor field, with the tumor tissue removed.
Bar¼1 mm¼ 2.5mm. (a) Sequence chromatogram of exon 11, obtained from
the microdissected tumor cells of patient TQ27 (PCR and sequencing with
primers BHD12F and BHD13cR). The 11 bp deletion is clearly present in the
heterozygous state.
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numbers of healthy cells in the analysis of total biopsy
material are not obscuring the results. Of note, LOH was only
detected in a minority of BHD syndrome-associated renal
malignancies (Khoo et al., 2003) to date, whereas compar-
able studies in the characteristic skin tumors associated with
this disease have, to the best of our knowledge, not been
carried out yet. In most BHD syndrome-associated malignant
kidney tumors, the healthy allele is lost by somatic mutations
(Vocke et al., 2005) that were not detectable in fibrofollicu-
lomas of our patients. Our results obtained in fibrofolliculo-
mas from BHD patients suggest that tumorigenesis in this
syndrome does not necessarily reflect the consequence of a
complete loss of folliculin function. Rather, haplo-insuffi-
ciency may be sufficient to cause uncontrolled growth and
subsequent carcinogenesis in susceptible tissues. If this is also
the case for the renal microscopic oncocytic proliferations in
BHD syndrome (Pavlovich et al., 2002) remains to be
determined. These lesions are thought to be the precursors
to malignant kidney tumors. From our findings, we would
expect microscopic oncocytosis to be heterozygous for the
BHD germline mutation.
MATERIALS AND METHODS
Case reports
All patients initially presented for diagnosis and treatment of flesh-
colored papules on the face that occurred from age 30–35 years
onward (Figure 3, patient MC60). The specific details of each
patient, including the family history, are listed in Table 2. Of note,
one patient had been misdiagnosed with acne vulgaris first and,
therefore, treated with isotretinoin, leading to a reportedly significant
regression of the skin lesions. None of the patients had suffered from
pneumothorax or renal carcinomas at the moment of presentation,
although patient KD63 had a history of spontaneous pneumothorax.
Thoracic X-ray examination was normal in all patients and screening
for renal malignancies by magnetic resonance imaging did not
reveal pathological findings in any of the patients. Although there are
no established guidelines for follow-up in BHD syndrome and
kidney tumors typically develop from the fifth decade of life onward
(Pavlovich et al., 2005), we did offer our patients yearly screening by
abdominal ultrasound examination.
In every patient, a skin biopsy for histological examination was
taken. A representative image (from patient TQ27) is depicted in
Figure 4. All biopsies revealed anastomosing epithelial strands
that are characteristic of fibrofolliculomas, with the majority of the
biopsy volume typically occupied by the tumor. To study the
splicing pattern of BHD mRNA and for the detection of possible
LOH, we isolated RNA and DNA from the tumors of three patients,
MH63, MC60, and MMC59.
We obtained informed consent from the patients for all
experimental procedures in accordance with institutional require-
ments and the Declaration of Helsinki Principles.
PCR and mutation detection
DNA was isolated from peripheral blood samples using a salt
precipitation technique described elsewhere (Miller et al., 1988). All
coding regions and the adjacent splice sites of the BHD gene were
amplified by PCR (primer sequences are listed in Table 3). PCR
Figure 3. Patient MC60. Typical distribution of numerous flesh-colored
papules in the face.
Table 2. Patient characteristics
Patient
Age at presentation
(years) Presenting symptom Family history Pneumothorax
Kidney
MRI
Thorax
X-ray
TQ27 77 Fibrofolliculoma Two affected sons,
multiple other affected
family members
No Normal Normal
MH63 42 Fibrofolliculoma Negative No Normal Normal
MC60 45 Fibrofolliculoma Sister (MMC59) affected No Normal Normal
MB61 44 Fibrofolliculoma Negative No Normal Normal
KD63 42 Fibrofolliculoma Negative Yes Normal Normal
MRI, magnetic resonance imaging.
100 m
Figure 4. The typical histology of a fibrofolliculoma, with its anastomosing
strands of epithelial cells. Bar¼1 mm¼ 100mm. The sample was obtained
from patient MC60.
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reactions (25ml) contained 1 buffer (Qiagen Benelux BV, Venlo,
The Netherlands), 0.2 mM dNTPs, 100 ng of each primer, 3% DMSO,
and 0.75 U Taq DNA polymerase (Qiagen). PCR conditions were;
30 seconds 941C, 30 seconds 621C, 60 seconds 721C for 35 cycles,
initiated by 90 seconds at 941C, and terminated by 7 minutes at 721C.
PCR products were purified with a MultiScreen-PCR filter plate
(Millipore, Billerica, MA) and subsequently directly sequenced
(BigDye deoxy terminator V3.1 cycle sequencing kit, Applied
Biosystems, Foster City, CA) with the aforementioned PCR primers,
according to the specifications of the manufacturer. Sequence analysis
was performed with the software tools Phred, Phrap, and Consed
(Ewing and Green, 1998; Ewing et al., 1998; Gordon et al., 1998).
The four novel mutations detected herein were excluded in
96 healthy controls by enzymatic digestion analysis. Mutation
420delC was confirmed with restriction endonuclease EcoO109I;
1408_1418delGGGAGCCCTGT with AlwNI; IVS10-2A4G with
AvaII; and 1300G4C with AleI, according to the manufacturer’s
instructions (all enzymes by New England Biolabs, Ipswich, MA).
RT-PCR and LOH studies
Skin punch biopsies (3 mm) of facial lesions were taken, after obtaining
informed consent from the patients. The tissue samples were snap
frozen in liquid nitrogen. RNA was extracted using the RNEasy mini kit
from Qiagen, according to the manufacturer’s recommendation. The
tissue was homogenized, without prior thawing, with a high-speed
stationary homogenizer. First-strand synthesis was performed using the
Superscript first-strand synthesis system (Invitrogen, Groningen, The
Netherlands) according to the manufacturer’s instructions. PCR was
then performed following the protocol outlined above. RT-PCR
products were analyzed on a 1.5% agarose gel. Individual PCR
products were isolated and directly sequenced.
For LOH analysis, DNA was isolated from snap-frozen biopsies
using the Puregene DNA isolation kit (Gentra Systems, Minneapolis,
MN) according to the manufacturer’s recommendations. Genomic
DNA of the biopsy material was subjected to PCR and direct
sequencing as described above.
Tissue processing for laser capture microdissection: Four micro-
meters tissue sections were incubated overnight at 561C, depar-
affinated with xylene, washed with 100% ethanol, stained with
hematoxylin, washed with water, dehydrated with increasing
percentage of ethanol and subsequently thoroughly dried.
Laser capture microdissection was performed on an Arcturus
PixCell II (Arcturus Engineering Inc., Mountain View, CA) micro-
scope using Arc200 version 2.0.0 (Arcturus Engineering Inc.)
imaging software. Approximately 100 ejected cells were captured
on plastic cups and collected in tissue lysis buffer with proteinase K.
Subsequently, DNA was extracted according to the manufacturer’s
protocol (DNeasy Tissue Kit, Qiagen). The DNA was subjected to
PCR using the conditions and primers outlined above. Multiple
tumor fields were dissected to allow for possible regional differences
in LOH.
The presence of promoter hypermethylation was assessed by
methylation-specific PCR as described previously (Herman et al.,
1996). We used the EZ DNA Methylation kit by Zymo Research
(Orange, CA) according to the manufacturer’s recommendations with
primers and conditions as described by Khoo et al. (2003). Briefly,
bisulfite converts unmethylated cytosines to uracil, whereas methylated
cytosine remains unchanged. The modified DNA is then amplified by
PCR. The methylated allele can be recognized by comparing its
restriction pattern or sequence with the unmethylated allele.
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